Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

Ähnliche Einträge

• Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension
  von: P. Vitulo, et al.
  Veröffentlicht: (2024)
• Pulmonary vascular disease, environmental pollution, and climate change
  von: Mona Lichtblau, et al.
  Veröffentlicht: (2024)
• Enhancing Drug Development for Paediatric Pulmonary Hypertension—An Integrative Perspective
  von: Steven H. Abman, et al.
  Veröffentlicht: (2025)
• The Interplay Between IL‐6, Hepcidin, and BMPR2 Signalling in Pulmonary Arterial Hypertension: Mechanistic Insights Into Vascular Remodelling
  von: Quezia K. Toe, et al.
  Veröffentlicht: (2026)
• Pulmonary Vascular Compromise Is Associated With Survival in Pediatric Pulmonary Hypertension: A New Computational Model
  von: Maria Niccum, et al.
  Veröffentlicht: (2025)